CSIMarket


Gilead Sciences Inc   (NASDAQ: GILD)
Other Ticker:  
 

Gilead Sciences Inc

GILD's Fundamental analysis








Looking into Gilead Sciences Inc growth rates, revenue grew by 6.4 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 1456

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -2.45 %

Gilead Sciences Inc 's net income grew by 25.83 % in IV. Quarter 2024 year on year, above company average,

More on GILD's Growth


Gilead Sciences Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 34.41 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
295.98
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.67.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.07.


More on GILD's Valuation
 
 Total Debt (Millions $) 26,711
 Dividend TTM ($) 3.13 $
 Dividend Yield TTM (%) 2.89 %
 Revenue/Employee (TTM) $ 1,597,444
 Net Income/Employee (TTM) $ 26,667
 Receivable Turnover (TTM) 6.27
 Tangible Book Value (Per Share $) -7.14

Gilead Sciences Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 34.41 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
295.98
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.67.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.07.

Gilead Sciences Inc Price to Book Ratio is at 6.98 lower than Industry Avg. of 17923.75. and higher than S&P 500 Avg. of 0.01

More on GILD's Valuation

  Market Capitalization (Millions $) 134,400
  Shares Outstanding (Millions) 1,263
  Employees 18,000
  Revenues (TTM) (Millions $) 28,754
  Net Income (TTM) (Millions $) 480
  Cash Flow (TTM) (Millions $) 3,906
  Capital Exp. (TTM) (Millions $) -523
  Total Debt (Millions $) 26,711
  Dividend TTM ($) 3.13 $
  Dividend Yield TTM (%) 2.89 %
  Revenue/Employee (TTM) $ 1,597,444
  Net Income/Employee(TTM) $ 26,667
  Receivable Turnover Ratio (TTM) 6.27
  Tangible Book Value (Per Share $) -7.14

  Market Capitalization (Millions $) 134,400
  Shares Outstanding (Millions) 1,263
  Employees 18,000
  Revenues (TTM) (Millions $) 28,754
  Net Income (TTM) (Millions $) 480
  Cash Flow (TTM) (Millions $) 3,906
  Capital Exp. (TTM) (Millions $) -523


    GILD's Profitability Comparisons
Gilead Sciences Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2024 to 32.4 % from 11.77 % in III. Quarter.

Gilead Sciences Inc net profit margin of 23.56 % is currently ranking no. 12 in Biotechnology & Pharmaceuticals industry, ranking no. 65 in Healthcare sector and number 661 in S&P 500.


Profitability by Segment
Total 16.61 %



  Ratio
   Capital Ratio (MRQ) 2.36
  Total Debt to Equity (MRQ) 1.39
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.51
  Inventory Turnover Ratio (TTM) 3.35



Gilead Sciences Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2024 to 32.4 % from 11.77 % in III. Quarter.

Gilead Sciences Inc net profit margin of 23.56 % is currently ranking no. 12 in Biotechnology & Pharmaceuticals industry, ranking no. 65 in Healthcare sector and number 661 in S&P 500.

More on GILD's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com